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T he cervical spine is commonly involved in patients with rheumatoid arthritis (RA) [1-3].  
Deterioration of the cervical spine in RA is a potentially 
serious disease manifestation that can result in progres-
sive neurological disability caused by mechanical cord 
compression and cervical spine instability [4 , 5].  
Cervical involvement is probably a consequence of the 
intense chronic synovitis that occurs in the joints of RA 
patients,  progressing to bone erosion and ligamentous 
laxity and finally clinical and radiological instability [6].  
This may be progressive with a resultant reduction in life 
expectancy [7].  It is thus essential to prevent the 
involvement of cervical lesions in RA,  achieving the 
treat-to-target (T2T) that is based on the European 
League Against Rheumatism (EULAR) recommenda-
tion [8 , 9].
Cervical involvement in RA includes three charac-
teristic instabilities: atlanto-axial subluxation (AAS),  
vertical subluxation (VS),  and subaxial subluxation 
(SAS).  Long disease duration and Steinbroker stage III 
or IV were reported to be risk factors for the presence of 
cervical lesions [10 , 11].  The clinical introduction of 
biological disease-modifying anti-rheumatic drugs 
(bDMARDs) has contributed to marked advances in the 
treatment of RA.  bDMARDs have been demonstrated 
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We investigated the prevalence of and risk factors for the progression of upper cervical lesions (UCLs) in 
patients with rheumatoid arthritis (RA).  A retrospective analysis of 49 patients with RA (4 males,  45 females) 
was conducted.  The UCLs included atlanto-axial subluxation and vertical subluxation.  We investigated the clin-
ical factors including the Disease Activity Score 28 based on C-reactive protein (DAS28-CRP) and the modified 
Health Assessment Questionnaire-Disability Index as well as radiographic changes between the baseline (at May 
2010 to April 2013) and final follow-up.  Forty patients (81.6%) were classified as the non-progressive group,  
and the other 9 patients (18.4%) comprised the progressive group.  The progressive group’s final CRP values,  
baseline or final MMP-3 levels,  DAS28-CRP,  and rate of pre-existing lesions at baseline were all significantly 
higher than those of the non-progressive group (p= 0.017,  p= 0.043,  p= 0.002,  p= 0.008,  p< 0.001,  and p= 0.008 
respectively).  A multivariate logistic regression analysis demonstrated that DAS28-CRP at baseline was a risk 
factor for radiographic progression (p= 0.018,  odds ratio: 2.54,  95% confidence interval: 1.17-5.51).  Our find-
ings indicate that higher disease activity might influence the progression of UCLs in patients with RA.
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to reduce RA disease activity and prevent structural 
joint damage to small joints such as those in the hand,  
wrist,  and forefoot [12 , 13].  Similarly,  there is evidence 
supporting the efficacy of bDMARDs for the treatment 
of cervical spine lesions,  but this remains controversial.  
Herein we investigated the prevalence of and risk fac-
tors for the progression of upper cervical lesions (UCLs) 
in patients with RA with relatively long disease dura-
tions.
Patients and Methods
This retrospective study was approved by the Ethics 
Committee of our institute (no. 2194).  The cases of 49 
patients (4 males,  45 females) with RA who had under-
gone dynamic plain cervical radiography > 2 times were 
analyzed.  Baseline radiographs were taken before 
orthopedic surgery other than spinal surgery between 
May 2010 and April 2013.  Patients who had a history of 
prior surgery,  prior trauma,  or any other symptomatic 
cervical spine condition were excluded.  All patients 
met both the American Rheumatism Association 1987 
revised criteria for RA [14] and 2010 RA classification 
criteria [15].  The patients’ mean age was 59.1 years 
(range 30-81 years); the mean disease duration was 
17.5 years (range 1-46 years),  and the mean follow-up 
period was 38.9 months (range 12-69 months).
According to Steinbroker radiographic grading [16],  
13 patients were categorized as stage III and 36 as stage 
IV.  According to Steinbroker functional classification 
[16],  one patient was categorized as class I,  43 patients 
as class II,  and 5 patients as class III.  Thirty-one 
patients (63.2%) were administered prednisolone (PSL) 
(4.8±2.3 mg/day),  and 31 patients (63.2%) were admin-
istered methotrexate (MTX) (7.8 ± 2.5 mg/week).  The 
bDMARDs administered at baseline were infliximab in 
4 patients,  etanercept in 10 patients,  adalimumab in 2 
patients,  tocilizumab in 2 patients,  and abatacept in 
one patient.
Radiographic assessment. Radiographic cervical 
lesions were defined as follows: an atlanto-dental inter-
val (ADI) of > 3 mm in the form of atlanto-axial sublux-
ation (AAS) [17 , 18],  and a Ranawat value < 13 mm as 
vertical subluxation (VS) [19].  Definitions of radio-
graphic progression were an increase in the ADI of 
> 2 mm for AAS,  and/or a decrease in the Ranawat 
value of > 2 mm for VS [20].  We divided the patients 
into 2 groups based on the results of their radiographic 
evaluation at study baseline: the Non-UCL group 
(n = 16) had no pre-existing upper cervical spine lesions,  
and the UCL group (n = 33) had AAS and/or VS.
Clinical assessment. The clinical assessment 
included the patient’s disease duration,  current medica-
tion (prednisolone/MTX/bDMARDs),  concentration of 
C-reactive protein (CRP),  rheumatoid factor (RF),  
Disease Activity Score 28 based on CRP (DAS28-CRP) 
[21],  matrix metalloproteinase-3 (MMP-3) value,  and 
modified Health Assessment Questionnaire-Disability 
Index (mHAQ) score [22] at baseline and at the patient’s 
final follow-up.
Statistical analysis. The statistical analyses were 
performed using R for Windows (www.r-project.org).  
We used Fisher’s exact test and the Mann-Whitney 
U-test for the comparisons of the 2 patient groups.  
P-values < 0.05 were considered significant.  To assess 
the risk factors of cervical lesions,  we performed a mul-
tiple logistic regression analysis.  Variables with p-values 
< 0.05 at the baseline in the univariate analysis were 
analyzed by the stepwise backward selection method.
Results
No significant differences were identified between 
the Non-UCL (n = 16) and UCL (n = 33) groups in terms 
of age,  gender,  interval of radiographic examination,  
the use of MTX,  and the use of PSL.  The disease dura-
tion and the use of bDMARDs in the UCL group were 
significantly higher than those in the Non-UCL group 
(p = 0.024 and p = 0.012,  respectively).  The rate of 
patients who were categorized as Steinbroker stage IV in 
the UCL group was significantly higher than that in the 
Non-UCL group (p = 0.016) (Table 1).  No significant 
differences were detected between the groups in terms 
of the baseline or final CRP value,  RF,  MMP-3 values,  
DAS28-CRP,  final mHAQ score,  or the rate of radio-
logical progression.  However,  the baseline mHAQ 
score in the UCL group was significantly higher than 
that in the Non-UCL group (p = 0.018) (Table 2).
Based on our definition of radiological progression,  
we classified 40 patients (81.6%) in the non-progressive 
group.  The other nine patients (18.4%) were classified 
as the progressive group.  No significant differences 
were observed between the progressive and non-pro-
gressive groups in terms of age,  gender,  disease dura-
tion,  interval of radiographic examination,  use of MTX,  
PSL,  or bDMARDs,  baseline CRP values,  baseline or 
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final RF,  or mHAQ at baseline and final follow-up.  
However,  the progressive group’s final CRP values 
(p = 0.017),  baseline (p = 0.043) and final (p = 0.002) 
MMP-3 levels,  and baseline (p = 0.008) and final 
(p < 0.001) DAS28-CRP and rate of pre-existing lesions 
(p = 0.008) at the baseline were all significantly higher 
than those of the non-progressive group (Table 3).
To compare the relative impact of these variables at 
baseline,  we performed a multiple logistic regression 
analysis.  We analyzed the three variables with p-values 
< 0.05 at the baseline in the univariate analysis (MMP-3 
level,  DAS28-CRP,  and pre-existing spine lesion) by the 
stepwise backward selection method.  The results of the 
multivariate logistic regression analysis revealed that a 
higher DAS28-CRP value at baseline was a risk factor 
for the radiographic progression of UCL (p = 0.018,  
odds ratio: 2.54,  95% CI: 1.17-5.51) (Table 4).
Discussion
Several research groups have examined the progres-
sion of cervical lesions in patients with RA.  In a study 
conducted over the course of 6 years,  the percentage of 
267 RA patients with any cervical instability increased 
from 47.6% at the beginning of follow-up to 70.4% by 
the end of the study [23].  In a 3.9-year study,  the pro-
gression of cervical spine lesions was observed in 42.9% 
of 91 patients [24].  In a cohort of patients with early 
RA,  cervical spine lesions were observed in 16% of the 
patients at 9 years.  It has also been proposed that the 
prevalence might decrease in subsequent years when 
more-intensive treatment strategies,  including 
bDMARDs,  are used in the early stage of the disease 
[25].
In the present study,  the percentage of patients with 
any cervical instability at baseline (65.3% of 49 patients) 
increased to 69.4% at the final follow-up.  Radiographic 
progression was observed in 9 (18.4%) cases,  which was 
lower than that observed in previous case studies 
[20 , 24].  Active and early treatment with DMARDs has 
been shown to prevent the development of cervical 
spine lesions due to RA [26].  A few longitudinal studies 
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????? ?　 Patientʼs background of each group
Non-UCL
n＝16
UCL
n＝33 P value
Age (years) 60.6 (30-81) 58.5 (32-74) 0.474
Gender (M : F) 1 : 15 3 : 30 1.000
Disease duration (years) 14.3 (1-46) 19.5 (1-46) 0.024＊
Follow-up period (month) 38.7 (12-64) 38.4 (12-69) 0.773
MTX,  n (%) 10 (62.5%) 21 (63.6%) 1.000
MTX (mg/week) 4.3 (0-12) 5.3 (0-15) 0.656
PSL,  n (%) 10 (62.5%) 21 (63.6%) 1.000
PSL (mg/day) 2.9 (0-10) 3.0 (0-10) 0.933
bDMARDs,  n (%) 2 (12.5%) 17 (51.5%) 0.012＊
Steinbroker stage IV,  n (%) 8 (50.0%) 28 (84.8%) 0.016＊
All values are expressed as mean (range).  ＊Statistically signiﬁcant 
(p＜0.05)
UCL,  upper cervical lesions; MTX,  methotrexate; PSL,  predniso-
lone; bDMARDs,  biologic disease-modifying antirheumatic drugs;  
CRP,  C-reactive protein; RF,  rheumatoid factor; MMP-3,  matrix 
metalloproteinase-3; DAS28,  Disease Activity Score 28; mHAQ,  
modiﬁed Health Assessment Questionnaire.
????? ?　 Patientʼs clinical parameters of each group
Non-UCL n＝16 UCL n＝33 P value
CRP (baseline,  mg/ml) 0.9 (0-2.6) 0.8 (0-4.7) 0.936
CRP (ﬁnal,  mg/ml) 0.3 (0-1.8) 0.3 (0-1.1) 0.526
RF (baseline,  mg/dl) 91.2 (5.1-448.9) 101.7 (1.5-474.9) 0.564
RF (ﬁnal,  mg/dl) 86.8 (1.6-332.1) 112.5 (1.5-1,115.5) 0.678
MMP-3 (baseline,  ng/ml) 144.4 (17.0-413.2) 164.2 (17.0-669.4) 0.872
MMP-3 (ﬁnal,  ng/ml) 101.2 (28.9-242.5) 137.0 (17.0-465.1) 0.235
DAS28-CRP (baseline) 3.3 (2.0-5.6) 3.2 (1.5-6.3) 0.890
DAS28-CRP (ﬁnal) 2.2 (1.1-3.8) 2.3 (1.1-3.7) 0.393
mHAQ (baseline) 0.5 (0-1.5) 0.8 (0-1.6) 0.018＊
mHAQ (ﬁnal) 0.6 (0-2.3) 0.8 (0-2.9) 0.189
progression,  n (%) 1 (6.3%) 8 (24.2%) 0.238
All values are expressed as mean (range).  ＊Statistically signiﬁcant (p＜0.05)
UCL,  upper cervical lesions; MTX,  methotrexate; PSL,  prednisolone; bDMARDs,  biologic disease-modifying antirheumatic drugs; CRP,  
C-reactive protein; RF,  rheumatoid factor; MMP-3,  matrix metalloproteinase-3; DAS28,  Disease Activity Score 28; mHAQ,  modiﬁed 
Health Assessment Questionnaire.
have suggested that DMARDs have an effect on cervical 
spine instability (CSI),  which may lead to reduced 
prevalence in the future [20 , 27].  On the other hand,  
some authors reported that MTX and biologics had no 
effect on CSI [11 , 28].
Kaito et al.  reported that the presence of pre-existing 
cervical spine lesions,  high baseline DAS28-CRP val-
ues,  and final MMP-3 levels were risk factors for the 
progression of cervical spine lesions [24].  In that study,  
a higher DAS28-CRP value at baseline was also found to 
be a risk factor for the progression of UCL.  Moreover,  
all patients with radiographic progression had more 
than moderate disease activity (MDA: DAS28-CRP 
> 2.7) at baseline,  and 8 of the patients had MDA even 
at final follow-up.  In the patients with UCLs,  both the 
rate of use of bDMARDs and the radiological progres-
sion of cervical lesions were higher compared to those 
of the patients without UCLs.  These results suggest that 
T2T is important to prevent the progression of cervical 
lesions,  regardless of the use of bDMARDs.
Some authors have reported that patients with CSI 
showed longer RA disease durations,  a higher RA stage,  
and higher mHAQ scores [10 , 11].  Our present analy-
ses revealed that all 49 of the patients were Steinbroker 
stage III or IV.  The average disease duration,  the rate of 
Steinbrocker stage IV,  and the mHAQ score in our 
patients with UCLs were significantly higher compared 
to those of the patients without UCLs.  These results 
suggest that long-term inflammation might cause the 
development of UCLs as well as peripheral joint 
destruction.  The levels of activities of daily living 
among RA patients might be decreased by instability of 
the cervical spine.
A recent meta-analysis showed that female gender,  
positive RF,  long-term corticosteroid treatment,  
peripheral joint erosion,  younger age,  long RA dura-
tion,  and higher disease activity markers were risk fac-
tors for CSI in patients with RA [29].  RA patients with 
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????? ?　 Multivariative analysis for predictive factors of the pro-
gression of cervical spine lesions
P value Odds Ratio 95% CI
DAS28-CRP (baseline) 0.018＊ 2.54 1.17-5.51
＊Statistically signiﬁcant (p＜0.05)
DAS28-CRP,  Disease Activity Score 28 on C-reactive protein.
????? ?　 Univariate analysis comparing the non-progressive and progressive groups
Non-progressive n＝40 Progressive n＝9 P value
Age (years) 58.9 (30-81) 60.3 (32-77) 0.542
Gender (M : F) 4 : 36 0 : 9 1.000
Disease duration (years) 18.5 (1-46) 17.2 (1-29) 0.901
Follow-up period (month) 37.6 (12-69) 42.1 (12-69) 0.688
MTX,  n (%) 27 (67.5%) 4 (44.4%) 0.259
MTX (mg/week) 4.9 (0-12) 5.2 (0-15) 0.751
PSL,  n (%) 24 (60.0%) 7 (77.8%) 0.454
PSL (mg/day) 2.8 (0-10) 4.0 (0-8) 0.160
bDMARDs,  n (%) 17 (42.5%) 2 (22.2%) 0.451
CRP (baseline,  mg/ml) 0.7 (0-2.9) 1.4 (0.3-4.7) 0.076
CRP (ﬁnal,  mg/ml) 0.3 (0-1.0) 0.8 (0-2.1) 0.017＊
RF (baseline,  mg/dl) 91.0 (1.5-474.9) 130.4 (1.5-452.6) 0.923
RF (ﬁnal,  mg/dl) 105.9 (1.5-1,115.5) 96.1 (1.5-393.7) 0.524
MMP-3 (baseline,  ng/ml) 146.0 (1.5-669.4) 205.7 (77.9-386.1) 0.043＊
MMP-3 (ﬁnal,  ng/ml) 102.5 (17.0-380.7) 235.3 (66.4-465.1) 0.002＊
DAS28-CRP (baseline) 3.1 (1.5-5.6) 4.1 (3.0-6.3) 0.008＊
DAS28-CRP (ﬁnal) 2.1 (1.1-3.8) 3.2 (1.1-4.0) ＜0.001＊
mHAQ (baseline) 0.7 (0-1.6) 0.9 (0.4-1.4) 0.133
mHAQ (ﬁnal) 0.7 (0-1.9) 1.2 (0.1-2.9) 0.068
Pre-existing spine lesion (baseline,  n (%)) 15 (37.4%) 8 (88.8%) 0.008＊
All values are expressed as mean (range).  ＊Statistically signiﬁcant (p＜0.05)
MTX,  methotrexate; PSL,  prednisolone; bDMARDs,  biologic disease-modifying antirheumatic drugs; CRP,  C-reactive protein; RF,  rheu-
matoid factor; MMP-3,  matrix metalloproteinase-3; DAS28,  Disease Activity Score 28; mHAQ,  modiﬁed Health Assessment Ques-
tionnaire.
a long disease duration have experienced more severe 
bone destruction and cervical involvement (especially 
patients with poor disease control).  Patients with a long 
course of RA are thus considered to have a higher prob-
ability of concurrent CSI,  due to the characteristic of 
chronic and persistent disease.  For the better treatment 
of rheumatoid cervical lesions,  early aggressive phar-
macological intervention before destruction of the liga-
ments might be required.  It would also be useful to 
detect rheumatoid upper cervical spine synovitis using 
advanced imaging modalities.
There are several limitations to the present study.  
First,  all patients were diagnosed with CSI,  according 
to the inpatient medical databases.  Because baseline 
radiographs were taken before orthopedic surgery,  all 
patients were Steinbrocker stage III or IV.  Therefore,  
the rate of pre-existing CSI was higher than those in 
previous studies [11 , 23 , 24].  Secondly,  the ability of 
plain radiographs to visualize bony erosions,  the 
craniocervical and cervicothoracic junctions,  and soft 
tissue abnormalities such as pannus and spinal cord 
compression is limited.  Because it was designed to shed 
light on upper cervical lesions,  this study lacked an 
analysis of SAS.  The development of SAS is reported to 
be a more multifactorial process compared to the devel-
opment of AAS and VS [26].  Thirdly,  these disease 
activity indicators reflected only a certain time point 
during the study period.
In conclusion,  higher DAS28-CRP at baseline was a 
risk factor for the progression of cervical spine lesions in 
our present series of RA patients with long-standing 
disease.  Early adequate pharmacological interventions 
might contribute to a decrease in the number of cervical 
spine lesions.
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